Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 9;11(3):826. doi: 10.3390/biomedicines11030826

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Therapeutic approaches for inhibiting CRPC progression as an alternative in mitigating the treatment resistance that occurs in CRPC. Abbreviations: ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; AR, androgen receptor; DNA, deoxyribonucleic acid; NGAT, next-generation anti-androgen therapy; PCa, prostate cancer; LBD, ligand binding domain; TGFβ, transforming growth factor beta; FGF, fibroblast growth factor; mTOR, mammalian target of rapamycin; AR-SV, androgen receptor-splice variant; SERM, selective estrogen receptor modulator; SERD, selective ER downregulator; CAPE, caffeic acid phenethyl ester; PROTAC, proteolysis targeting chimeras; CAR-T, chimeric antigen receptor (CAR)-T cell treatment.